financetom
Business
financetom
/
Business
/
US urges allies to tighten China's access to chip technology, Bloomberg reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US urges allies to tighten China's access to chip technology, Bloomberg reports
Mar 6, 2024 6:44 PM

March 6 (Reuters) - The U.S. government is urging the

Netherlands, Germany, South Korea and Japan to further tighten

curbs on China's access to semiconductor technology, Bloomberg

News reported on Wednesday.

The U.S. wants Japanese companies to limit exports to China

of specialized chemicals required for chipmaking, including

photoresist, the report said citing people familiar with the

matter.

Washington is also pressing the Netherlands to stop

semiconductor equipment maker ASML from servicing and

repairing chipmaking equipment for Chinese clients bought before

limits on sales of those devices were put in place this year, a

source familiar with the matter told Reuters, confirming part of

the Bloomberg report.

Tokyo and The Hague want to assess the impact of their

current curbs before considering tougher actions, the report

said, adding that the U.S. Commerce Department officials raised

the issue in Tokyo during a meeting on export controls last

month.

The Dutch foreign ministry declined to comment on the

report, while the U.S. Commerce Department did not respond to a

request for comment.

An official at Japan's industry ministry said the ministry

routinely discusses export controls with relevant countries.

ASML could not be immediately reached for comment.

American officials had earlier expressed particular concerns

about China's ability to employ advanced chips, and the powerful

processors they enable, for its fast-growing military.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ovid Therapeutics Q3 revenue slightly beats expectations
Ovid Therapeutics Q3 revenue slightly beats expectations
Nov 12, 2025
Overview * Ovid Therapeutics ( OVID ) Q3 revenue slightly beats analyst expectations * Meg Alexander appointed CEO, effective January 2026 Outlook * Ovid plans Phase 2a trial for OV329 in Q2 2026 * Company expects OV350 data in Q4 2025 * Ovid anticipates OV4071 clinical trial start in Q2 2026 Result Drivers * Research and development expenses were $5.9...
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
Nov 12, 2025
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007’s unique molecular attributes; strong patient enrollment continues Novel alopecia areata data including biomarkers from Phase 1b/2a study to be presented at upcoming Inflammatory...
TScan Therapeutics Q3 revenue jumps
TScan Therapeutics Q3 revenue jumps
Nov 12, 2025
Overview * TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements * Net loss for Q3 2025 increased due to higher R&D expenses * Company reached FDA agreement on pivotal trial design for TSC-101 Outlook * Company expects cash reserves to fund operations into the second half of 2027 * Enrollment in solid tumor trial paused to...
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Nov 12, 2025
07:14 AM EST, 11/12/2025 (MT Newswires) -- Loblaw Companies ( LBLCF ) said Wednesday that third-quarter adjusted earnings and revenue both rose, with both measures beating estimates. Adjusted earnings increased 8% to $828 million or $0.69 per diluted share, from $767 million, or $0.62 per diluted share in the prior year period. The result was a cent above the consensus...
Copyright 2023-2026 - www.financetom.com All Rights Reserved